ARTICLE | Top Story
Wilex plummets on Rencarex miss
October 17, 2012 12:45 AM UTC
Wilex AG (Xetra:WL6) fell EUR 2.40 (62%) to EUR 1.50 on Tuesday after Rencarex girentuximab missed the primary endpoint of improving median disease-free survival (DFS) vs. placebo in the Phase III ARISER trial to treat clear cell renal cell carcinoma (RCC). ARISER was evaluating once-weekly Rencarex for 24 weeks following complete or partial surgical removal of the affected kidney in patients with no detectable metastases. Rencarex is a chimeric mAb against carbonic anhydrase IX (CAIX). ...